Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.lpm.2008.12.033 | DOI Listing |
Fam Med
November 2024
American Board of Family Medicine, Lexington, KY.
Background And Objectives: Because deaths from opioid overdoses have increased in the United States, family physicians are needed who can provide integrated care for a patient with HIV, hepatitis C, and opioid use disorder. We sought to describe the individual and residency characteristics of graduating family medicine residents who intend to practice such integrated care.
Methods: We used 2017-2021 data from the American Board of Family Medicine Initial Certification Questionnaire.
Hepatol Commun
December 2024
Department of Infectious Diseases, Vestfold Hospital Trust, Tønsberg, Norway.
Background: Little is known about the determinants of disease progression among African patients with chronic HBV infection.
Methods: We used machine-learning models with longitudinal data to establish predictive algorithms in a well-characterized cohort of Ethiopian HBV-infected patients without baseline liver fibrosis. Disease progression was defined as an increase in liver stiffness to >7.
Viruses
December 2024
Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide 5000, Australia.
Background: Point-of-care hepatitis C virus (HCV) testing streamlines testing and treatment pathways. In this study, we established an HCV model of care in a homelessness service by offering antibody and RNA point-of-care testing.
Methods: A nurse and peer-led HCV model of care with peer support were implemented between November 2021 and April 2022 at a homelessness service in Adelaide, Australia.
Viruses
November 2024
Laboratory Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
The HIV integrase inhibitor, dolutegravir (DTG), in the absence of eliciting integrase (int) resistance, has been reported to select mutations in the virus 3'-polypurine tract (3'-PPT) adjacent to the 3'-LTR U3. An analog of DTG, cabotegravir (CAB), has a high genetic barrier to drug resistance and is used in formulations for treatment and long-acting pre-exposure prophylaxis. We examined whether mutations observed for DTG would emerge in vitro with CAB.
View Article and Find Full Text PDFToxics
December 2024
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Entecavir (ETV) is an antiviral used to treat chronic infection caused by the hepatitis B virus, which affects approximately 250 million people worldwide. In order to mitigate the impacts of ETV on the environment, including potential harm to human health, this study evaluated the use of the Fenton-like reaction, which uses iron complexed with ethylenediaminetetraacetic acid (EDTA) at neutral pH, and the microbiological action of in removing ETV from the aqueous medium. Aqueous concentrations of 100 mg/L were subjected to Fenton-like degradation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!